X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs GLENMARK PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA GLENMARK PHARMA AUROBINDO PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 14.2 12.6 112.7% View Chart
P/BV x 2.9 2.3 127.2% View Chart
Dividend Yield % 0.4 0.5 93.7%  

Financials

 AUROBINDO PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
GLENMARK PHARMA
Mar-18
AUROBINDO PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs809930 87.0%   
Low Rs504517 97.4%   
Sales per share (Unadj.) Rs281.1322.6 87.1%  
Earnings per share (Unadj.) Rs41.428.5 145.2%  
Cash flow per share (Unadj.) Rs50.939.2 129.8%  
Dividends per share (Unadj.) Rs2.502.00 125.0%  
Dividend yield (eoy) %0.40.3 137.8%  
Book value per share (Unadj.) Rs199.4183.0 108.9%  
Shares outstanding (eoy) m585.88282.17 207.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.32.2 104.1%   
Avg P/E ratio x15.925.4 62.5%  
P/CF ratio (eoy) x12.918.5 69.9%  
Price / Book Value ratio x3.34.0 83.3%  
Dividend payout %6.07.0 86.1%   
Avg Mkt Cap Rs m384,630204,206 188.4%   
No. of employees `00017.313.7 126.4%   
Total wages/salary Rs m21,30818,718 113.8%   
Avg. sales/employee Rs Th9,500.76,636.8 143.2%   
Avg. wages/employee Rs Th1,229.41,364.7 90.1%   
Avg. net profit/employee Rs Th1,397.9586.1 238.5%   
INCOME DATA
Net Sales Rs m164,66691,031 180.9%  
Other income Rs m1,020914 111.6%   
Total revenues Rs m165,68691,945 180.2%   
Gross profit Rs m37,71816,154 233.5%  
Depreciation Rs m5,5803,019 184.8%   
Interest Rs m7772,856 27.2%   
Profit before tax Rs m32,38011,193 289.3%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,1833,155 259.4%   
Profit after tax Rs m24,2298,039 301.4%  
Gross profit margin %22.917.7 129.1%  
Effective tax rate %25.328.2 89.7%   
Net profit margin %14.78.8 166.6%  
BALANCE SHEET DATA
Current assets Rs m121,87869,887 174.4%   
Current liabilities Rs m86,80632,879 264.0%   
Net working cap to sales %21.340.7 52.4%  
Current ratio x1.42.1 66.1%  
Inventory Days Days13081 159.5%  
Debtors Days Days6893 73.1%  
Net fixed assets Rs m81,03728,892 280.5%   
Share capital Rs m586282 207.6%   
"Free" reserves Rs m116,21851,353 226.3%   
Net worth Rs m116,80451,635 226.2%   
Long term debt Rs m4,51241,418 10.9%   
Total assets Rs m211,052125,954 167.6%  
Interest coverage x42.74.9 867.2%   
Debt to equity ratio x00.8 4.8%  
Sales to assets ratio x0.80.7 108.0%   
Return on assets %11.88.6 137.0%  
Return on equity %20.715.6 133.2%  
Return on capital %27.415.1 181.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72736,317 222.3%   
Fx outflow Rs m34,7009,720 357.0%   
Net fx Rs m46,02726,598 173.0%   
CASH FLOW
From Operations Rs m19,54816,481 118.6%  
From Investments Rs m-19,570-10,133 193.1%  
From Financial Activity Rs m8,642-4,685 -184.5%  
Net Cashflow Rs m8,9221,770 504.1%  

Share Holding

Indian Promoters % 54.1 48.3 112.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 6.9 115.2%  
FIIs % 27.7 34.4 80.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 10.5 97.1%  
Shareholders   69,601 56,727 122.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  ELDER PHARMA  GSK PHARMA  PANACEA BIOTECH  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips below 38,000-Mark; Yes Bank Jumps 9%(12:30 pm)

Share markets in India are presently trading deep in the red as investors were disappointed after the government refused any respite to foreign investors.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jul 22, 2019 03:13 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS